Form 8-K May 29, 2018				
UNITED STATES				
SECURITIES AND EXCH	ANGE COMMISSION			
Washington, D.C. 20549				
FORM 8-K				
CURRENT REPORT				
Pursuant to Section 13 or 13	5(d) of the Securities Exchan	ge Act of 1934		
Date of Report (Date of earliest event reported): May 23, 2018				
BioLargo, Inc.				
(Exact name of registrant as specified in its charter)				
Delaware	000-19709	65-0159115		
(State or other jurisdiction	(Commission File Number)	(IRS Employer		
of incorporation)		Identification No.)		

BIOLARGO, INC.

Edgar Filing: BIOLARGO, INC. - Form 8-K

14921 Chestnut St., Westminster, California 92683

(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (949) 643-9540
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders

The Company held its 2018 annual stockholder meeting on May 23, 2018. The following matters were each submitted to a vote of stockholders through the solicitation of proxies or otherwise:

- 1. A proposal to elect the following seven individuals to our Board of Directors: Dennis P. Calvert, Kenneth R. Code, Dennis E. Marshall, Joseph L. Provenzano, Kent C. Roberts II, John S. Runyan and Jack B. Strommen.
- 2. Advisory approval of the Company's executive compensation.
- $_3$. A proposal to ratify the appointment of Haskell & White LLP as our independent public accounting firm for the $_2018$ fiscal year.
- 4. A proposal to increase the authorized capital stock of the Company from 200,000,000 shares of common stock to 400,000,000 shares of common stock.
- 5. A proposal to adopt the 2018 Equity Incentive Plan.

A quorum was present in person or by proxy. Each matter was approved. The voting results are as follows:

			Total Votes
	Votes	Broker	
Proposal One	Votes For		(For +
	Withheld	Non-Vote	
			Withheld)
Dennis P. Calvert	34,827,821640,290	35,954,467	35,468,111
Kenneth R. Code	34,848,821619,290	35,954,467	35,468,111
Dennis E. Marshall	35,086,896381,215	35,954,467	35,468,111
Joseph L. Provenzano	34,737,572730,539	35,954,467	35,468,111
Kent C. Roberts II	35,234,614233,497	35,954,467	35,468,111
John S. Runyan	35,204,734263,377	35,954,467	35,468,111
Jack B. Strommen	35,113,776354,335	35,954,467	35,468,111
	Votes	Votes	Broker Non-
Proposals 2 - 5	Votes For		Total votes
	Against	Abstain	Vote
2	34,117,9191,102,804	247,388	35,954,46735,468,111

Edgar Filing: BIOLARGO, INC. - Form 8-K

3	69,640,818 357,915	1,423,844	- 71,422,577
4	60,800,6137,946,285	2,596,033	79,64771,342,931
5	33.976.1461.201.591	290.374	35.954.46735.468.111

For the Advisory Approval of Executive Compensation, prior year votes are as follows:

Year Votes For Votes Against Votes Abstain

		Non-Vote
2017 27,248,643	343,971	242,499 28,177,525
2016 31,052,733	342,142	240,267 21,119,013

There were no director nominees other than as set forth above.

Edgar Filing: BIOLARGO, INC. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:

May BIOLARGO, INC. 29,

2018

By: /s/ Dennis P. Calvert Dennis P. Calvert

President and Chief Executive Officer